

TRANSMITTAL FORM

(To be used for all correspondence after initial filing)

| Application Number | 10/624,946 | |
|----------------------|--------------------|--|
| Filing Date | July 21, 2003 | |
| First Named Inventor | Jeffrey R. Raymond | |
| Art Unit | Not Assigned | |
| Examiner Name | Not Assigned | |
| Attorney Docket No. | 480117.407C1 | |

| Fee Transmittal Form Fee Attached Amendment/Response After Final Affidavits/declaratio Extension of Time Requ Express Abandonment Request Information Disclosure Statement; Form PTO-1 (2 Sheets) Cited References Certified Copy of Priority Document(s) Response to Missing Pa | Petition to Convert to a Provisional Application Power of Attorney, Revocation, Change of Correspondence Address Declaration Statement under 37 CFR 3.73(b) Terminal Disclaimer Request for Refund | CD(s), Number of CD(s) After Allowance Communication to Group Appeal Communication to Board of Appeals and Interferences Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) Proprietary Information Status Letter Return Receipt Postcard Additional Enclosure(s) (please identify below): |
|--|---|--|
| Response to Missing Parts/Incomplete Applic | | |
| Remarks | • | |
| SIGN | ATURE OF APPLICANT, ATTORNEY, | OR AGENT |
| Individual Name Carol J | i i | Customer Number 00500 |
| Signature (1) | rol & Rotm | |
| | 20, 2003 | |
| | CERTIFICATE OF TRANSMISSION/MA | AILING |
| I hereby certify that this cor with the United States Post | respondence is being facsimile transmit al Service with sufficient postage as firster for Patents, P.O. Box 1450, Alexandr | ted to the USPTO or deposited t class mail in an envelope |
| Typed or printed name | Lawrence Teague | |
| Signature This collection of information is forwised to 3 | Lawren Jeagne | Date: October 20, 2003 |
| preparing, and submitting the completed app require to complete this form and/or suggesti | CFR 1.5. The information is required to obtain or retain a benefit verned by 35 U.S.C. 122 and 37 CFR 1.13. This collection is estimication form to the USPTO. Time will vary depending upon the indons for reducing this burden, should be sent to the Chief Informatic exandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE Alexandria, VA 22313-1450. | lividual case. Any comments on the amount of time you on Officer, U.S. Patent and Trademark Office, U.S. |

PATENT

I hereby certify that on the date specified below, this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

October 20, 2003

Lawrence Teague

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants

Jeffrey R. Raymond et al.

Application No.

10/624,946

Filed

July 21, 2003

For

3-NITROGEN-6,7-DIOXYGEN STEROIDS AND USES

RELATED THERETO

Docket No.

: 480117.407C1

Date

: October 17, 2003

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents:

In accordance with 37 C.F.R. §§ 1.56 and 1.97 through 1.98, applicants wish to make known to the Patent and Trademark Office the references set forth on the attached Forms PTO-1449. This application is a continuation and relies, under 35 U.S.C. § 120, on the earlier filing date of prior Application No. 09/845,775, filed April 30, 2001, now issued as U.S. Patent 6,635,629. The references listed on the attached Forms PTO-1449 were submitted to and/or cited by the Patent and Trademark Office in this prior application and, therefore, are not required to be provided in the present application. If the Examiner wishes, copies will be provided upon request.

Although the aforesaid references are made known to the Patent and Trademark Office in compliance with applicants' duty to disclose all information they are aware of which is believed relevant to the examination of the above-identified application, applicants believe that their invention is patentable.

Please acknowledge receipt of this Information Disclosure Statement and kindly make the cited references of record in the above-identified application.

Applicants believe this Information Disclosure Statement has been timely filed, however, the Director is authorized to charge any fee due by way of this Information Disclosure Statement to our Deposit Account No. 19-1090.

Respectfully submitted,
Jeffrey R. Raymond

Carol of Rotm

Seed Intellectual Property Law Group PLLC

Carol J. Roth

Registration No. 32,783

CJR:ljt

Enclosures:

Postcard Transmittal Form Form PTO-1449 (2 Sheets)

701 Fifth Avenue, Suite 6300 Seattle, Washington 98104-7092

Phone: (206) 622-4900 Fax: (206) 682-6031

\426117

FORM PTO 1449 (REV.7-80) INFORMATION DISCLOSURE STATEMENT

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

(Use several sheets if necessary)

ATTY. DOCKET NO. 480117.407C1 APPLICATION NO. 10/624,946

APPLICANTS

Jeffrey R. Raymond et al.

FILING DATE

GROUP ART UNIT

July 21, 2003

Not Assigned

U.S. PATENT DOCUMENTS

| *EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE |
|----------------------|----|-----------------|----------|------------------|-------|----------|-------------------------------|
| | AA | 5,637,691 | 06/10/97 | Frye et al. | 540 | 106 | |
| | AB | 5,721,226 | 02/24/98 | Frye et al. | 514 | 169 | |
| | AC | 5,733,899 | 03/31/98 | Frye et al. | 514 | 169 | |
| | AD | 5,817,632 | 10/06/98 | Hsia | 514 | 21 | |
| | AE | 5,847,172 | 12/08/98 | Zasloff et al. | 552 | 521 | |
| | AF | 5,856,535 | 01/05/99 | Zasloff et al. | 552 | 521 | |
| | AG | 5,874,597 | 02/23/99 | Jones | 552 | 521 | |
| • | AH | 6,046,185 | 04/04/00 | Burgoyne et al. | 514 | 178 | |
| | AI | 6,060,465 | 05/09/00 | Miljkovic et al. | 514 | 169 | |
| | AJ | | | | | | |

FOREIGN PATENT DOCUMENTS

| | DOCUMENT | DATE | COUNTRY | TRANS | LATION |
|------|-------------|----------|---------|-------|--------|
| | NUMBER | DATE | COUNTRY | YES | NO |
| AK | WO 91/10743 | 07/25/91 | WIPO | | |
| AL | WO 94/14451 | 07/07/94 | WIPO | | |
| AM | WO 94/20520 | 09/15/94 | WIPO | | |
| AN | WO 96/22791 | 08/01/96 | WIPO | | |
| АО | WO 96/36230 | 11/21/96 | WIPO | | |

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

| AP | Cram and Allinger, "Mold Metabolites. VIII. Contribution to the Elucidation of the Structure of |
|----|--|
| | Helvolic Acid," Journal of the American Chemical Society 78:5275-5284, October 20, 1956. |
| AQ | Foussard-Blanpin, "Pharmacological Study of 3α-Aminopregnane," Ann. Pharm. FR. |
| | 27(3):191-200, 1969. (Abstract Only, STN Accession No. 71:79454) |
| AR | McGowan et al., "The Production of a Reactive Oxygen Intermediate during the Induction of Apoptosis by Cytotoxic Insult," <i>Experimental Cell Research 238</i> (1):248-256, |
| | January 10, 1998. |

EXAMINER

DATE CONSIDERED

* EXAMINER:

Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

| | / | 0 | Ů v | 45 | 6 | |
|--------|-----------|-----|-----|------|-----|-------------|
| فسمه ر | (P | OCT | 2 | 3 20 | 103 | ; ; ; |
| | · ` · · ` | | | | | • |

| 1.3 | |
|-------------------|----|
| FORM PTO-1449 (5) | ٠, |
| (REV.7-80) | |

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO. 480117.407C1

APPLICATION NO. 10/624,946

APPLICANTS

| INFORMATION DISCLOSURE STATEMENT |
|----------------------------------|
|----------------------------------|

(Use several sheets if necessary)

Jeffrey R. Raymond et al.

FILING DATE

GROUP ART UNIT

July 21, 2003

Not Assigned

U.S. PATENT DOCUMENTS

| *EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE |
|----------------------|----|-----------------|------|------|-------|----------|-------------------------------|
| | ВА | | | | | | |
| | вв | | | | | | |
| | вс | | | | | | |
| | BD | | | | | | |
| • | BE | | | | | | |
| | BF | | | | | | |
| | ВG | | | | | | |
| • | вн | | | | | | |
| • | ві | | | | | | |
| | ВЈ | | | | | | |

FOREIGN PATENT DOCUMENTS

| | DOCUMENT | DATE | COUNTRY | TRANS | LATION |
|------|-------------|----------|---------|-------|--------|
| | NUMBER | DATE | COUNTRI | YES | NO |
| ВК | WO 98/02450 | 01/22/98 | WIPO | | |
| BL | WO 98/27106 | 06/25/98 | WIPO | | |
| ВМ | WO 99/44616 | 09/10/99 | WIPO | | |
| BN | | | | | |
| во | | | | | |

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

| ВР | Mendenhall et al., "Anabolic Steriod Effects on Immune Function: Differences Between Analogs," <i>J. Steriod Biochem. Mol. Biol</i> 37(1):71-76, 1990. (Abstract Only, STN Accession No. 114:17714) |
|----|---|
| BQ | Spyriounis et al., "Novel N-Substituted 3-Aminosteroids Which Exhibit Anti-Inflammatory Properties and Influence Free Radical Processes," Eur. J. Med. Chem. 28(6):521-525, 1993. |
| BR | |

EXAMINER

DATE CONSIDERED

* EXAMINER:

Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).